Paronychia is inflammation of the skin surrounding the nail that leads to secondary infection. Iatrogenic paronychia has been clearly associated with cancer chemotherapies. This phase-2 trial is a dose finding study and will evaluate topical VBP-926 solution against a vehicle control.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
102
Topical VBP-926 solution
Compassionate Cancer Care
Fountain Valley, California, United States
Northwestern University Department of Dermatology
Chicago, Illinois, United States
Washington University
St Louis, Missouri, United States
Memorial Sloan Kettering Cancer Center
Downgrading of the 6-point Paronychia Severity Grading scale (adapted from CTCAE v4.0) in adult cancer patients with chemotherapy-associated paronychia
Treatment responses will be assessed by clinical grading utilizing a morphologic 6-point Paronychia Severity Grading scale (adapted from CTCAE v4.0) and will be assessed from baseline to 8 weeks for each affected nail.
Time frame: 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
New York, New York, United States
Montefiore Einstein Center for Cancer Care
The Bronx, New York, United States
Oncology Specialists of Charlotte
Charlotte, North Carolina, United States
Ohio State University
Columbus, Ohio, United States
Bryn Mawr Skin & Cancer Institute
Bryn Mawr, Pennsylvania, United States